Welcome to a world with an easy, fast, and effective solution to tricuspid regurgitation

Contact Us

TriPair is the solution for tricuspid interventions

Tricuspid regurgitation (TR) is a life-threatening condition that can lead to heart failure, end-organ damage such as liver failure, repeated hospitalizations, and death. Many millions suffer from moderate or severe TR, and the three-year survival rate for severe cases is less than 50%.

The Coramaze TriPair System brings healing to patients without access to alternative therapies.

TriPair Tricuspid Repair System

TriPair Tricuspid Repair System in Action

TriPair Advantages

Easy

Designed for effortless
excellence

Streamlined procedural steps leveraging standard catheterization techniques

Fluoro-based deployment with fast
learning curve

Fast

Straightforward procedure with device time less than 20 minutes

No anesthesia and no TEE, ensuring high turn-around time in the cathlab

Effective

Flexible inflatable spacer fills the leaflet gaps

Atraumatic and effective regardless of
valve morphology

Repeatable thoracic echo-based efficacy testing for optimal outcomes

About Coramaze

Coramaze Technologies was founded in 2013 as a tech-transfer from Duisburg-Essen university. It is committed to the improvement of structural heart patients’ lives by developing accessible and effective minimally invasive treatments. Our team holds a successful record in R&D of cardiovascular devices, regulatory affairs for global markets, and multicenter clinical investigations.

Jochen Reinöhl

CEO

Boaz Harari

CTO

M.Sc. Ido Sadan

VP R&D

Dr. Michal Shohat

VP Clinical Affairs

Contact Us

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Israel Office

3 Totseret ha-Arets St, Building I, Floor 22, Petah Tikva, 4951734, Israel
office@coramaze.com
+972.3.7479146

Germany Office

Mühlenhof 7-9, D-40721 Hilden, Germany

© Coramaze Technologies All Rights Reserved // Design by: Studio Kukushka // Build by: Vivir Studio